DK1838341T3 - Vaccinesammensætning omfattende et fibronectin bindende protein eller et fibronectinbindende peptid - Google Patents

Vaccinesammensætning omfattende et fibronectin bindende protein eller et fibronectinbindende peptid

Info

Publication number
DK1838341T3
DK1838341T3 DK06701328.4T DK06701328T DK1838341T3 DK 1838341 T3 DK1838341 T3 DK 1838341T3 DK 06701328 T DK06701328 T DK 06701328T DK 1838341 T3 DK1838341 T3 DK 1838341T3
Authority
DK
Denmark
Prior art keywords
fibronectin binding
vaccine composition
binding protein
binding peptide
peptide
Prior art date
Application number
DK06701328.4T
Other languages
English (en)
Inventor
Bror Morein
Karin Loevgren-Bengtsson
Birgitta Fromgren
Jill Ekstroem
Carlos Baschunan
Katarina Ranlund
Original Assignee
Isconova Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isconova Ab filed Critical Isconova Ab
Application granted granted Critical
Publication of DK1838341T3 publication Critical patent/DK1838341T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DK06701328.4T 2005-01-20 2006-01-20 Vaccinesammensætning omfattende et fibronectin bindende protein eller et fibronectinbindende peptid DK1838341T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59350405P 2005-01-20 2005-01-20
PCT/SE2006/000082 WO2006078213A1 (en) 2005-01-20 2006-01-20 Vaccine composition comprisinga fibronectin binding protein or a fibronectin binding peptide

Publications (1)

Publication Number Publication Date
DK1838341T3 true DK1838341T3 (da) 2013-11-04

Family

ID=36692518

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06701328.4T DK1838341T3 (da) 2005-01-20 2006-01-20 Vaccinesammensætning omfattende et fibronectin bindende protein eller et fibronectinbindende peptid

Country Status (9)

Country Link
US (2) US8007806B2 (da)
EP (1) EP1838341B1 (da)
CN (1) CN101107009B (da)
BR (1) BRPI0606481A2 (da)
CA (1) CA2592627C (da)
DK (1) DK1838341T3 (da)
ES (1) ES2433467T3 (da)
PL (1) PL1838341T3 (da)
WO (1) WO2006078213A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090053235A1 (en) * 2006-06-12 2009-02-26 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
JP2008013447A (ja) * 2006-07-03 2008-01-24 Juntendo 毒素検出方法
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
JP5658564B2 (ja) 2007-08-31 2015-01-28 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
US8758765B2 (en) 2008-07-29 2014-06-24 The University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
EP3281947B1 (en) 2009-04-03 2020-02-12 The University of Chicago Compositions and methods related to protein a (spa) variants
ES2655701T3 (es) 2010-07-02 2018-02-21 The University Of Chicago Composiciones y métodos relacionados con variantes de la proteína A (SpA)
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
CN102993278B (zh) * 2012-09-29 2014-02-19 重庆原伦生物科技有限公司 耐甲氧西林金黄色葡萄球菌(MRSA)疫苗重组蛋白抗原FnbA1的纯化方法
CA2900008C (en) 2013-02-07 2025-10-07 Children's Medical Center Corporation PROTEIN ANTIGENS THAT CONFER PROTECTION AGAINST COLONIZATION AND/OR PNEUMOCOCCAL DISEASE
CN106680483A (zh) * 2015-11-06 2017-05-17 中创云牧(内蒙古)科技咨询有限公司 金黄色葡萄球菌黏附素蛋白抗体的抗黏附能力的检测方法
WO2017153993A1 (en) * 2016-03-09 2017-09-14 Technion Research And Development Foundation Ltd. Liposomal formulations and methods of using same in agriculture
JP7551496B2 (ja) 2017-10-31 2024-09-17 カリヴィル イムノセラピューティクス， インコーポレイテッド 全身送達のためのプラットフォーム腫瘍溶解性ベクター
WO2019226529A1 (en) * 2018-05-21 2019-11-28 Bioprocessia Technologies Llc Multivalent protein complexes
AU2020273471B2 (en) 2019-05-14 2026-05-07 The University Of Chicago Methods and compositions comprising Staphylococcus protein A (SpA) variants
US12528882B2 (en) 2019-09-13 2026-01-20 The University Of Chicago Methods and compositions for treating staphylococcal infections
PE20231175A1 (es) 2020-11-19 2023-08-01 Kalivir Immunotherapeutics Inc Inmunoterapia oncolitica por remodelacion del microambiente tumoral
IL316712B2 (en) 2021-04-30 2025-12-01 Kalivir Immunotherapeutics Inc Oncolytic viruses for modified mhc expression
SE2200142A1 (en) * 2022-12-13 2024-06-14 Savacc Ab Chrisvacc

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US5540933A (en) 1985-05-31 1996-07-30 La Jolla Cancer Research Foundation Isolation and use of fibronectin receptor
ATE71303T1 (de) 1986-01-14 1992-01-15 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
JPH04503114A (ja) 1989-09-08 1992-06-04 ウイスコンシン　アラムナイ　リサーチ　フオンデーション ブドウ球菌フィブロネクチン受容体抗体の検出試験
NL9000207A (da) 1990-01-29 1991-08-16 Duphar Int Res
US5270168A (en) 1990-02-21 1993-12-14 Board Of Regents, The University Of Texas System Method for diagnosing non-healing ulcers
NL9002314A (nl) 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
US5618916A (en) 1993-01-06 1997-04-08 The Jewish Hospital Of St. Louis Purified protein which functions as a mycobacterial receptor for fibronectin
WO1995024470A1 (en) 1994-03-09 1995-09-14 Pacific Biotech International, Inc. Activating virus
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US20010053365A1 (en) * 1995-04-25 2001-12-20 Smithkline Beecham Biologicals S.A. Vaccines
US5753235A (en) 1996-02-15 1998-05-19 Heska Corporation Recombinant canine herpesviruses
SE9600647D0 (sv) 1996-02-21 1996-02-21 Bror Morein Ny användning
CA2255669A1 (en) * 1996-05-16 1997-11-20 The Texas A & M University System Collagen binding protein compositions and methods of use
PT835930E (pt) 1996-10-09 2001-06-29 Akzo Nobel Nv Estirpes europeias de vacina do virus do sindroma reprodutivo e respiratorio porcino (prrsv)
US6231859B1 (en) 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
US6685943B1 (en) * 1997-01-21 2004-02-03 The Texas A&M University System Fibronectin binding protein compositions and methods of use
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
DK1545605T3 (da) 2002-10-02 2010-04-12 Nordic Vaccine As Komposition til vaccination
SE0300795D0 (sv) 2003-03-24 2003-03-24 Isconova Ab Composition comprising iscom particles and live micro-organisms
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof

Also Published As

Publication number Publication date
US8007806B2 (en) 2011-08-30
EP1838341A1 (en) 2007-10-03
EP1838341B1 (en) 2013-08-14
CN101107009A (zh) 2008-01-16
ES2433467T3 (es) 2013-12-11
BRPI0606481A2 (pt) 2009-06-30
US20090208562A1 (en) 2009-08-20
CA2592627C (en) 2014-02-25
US20110303563A1 (en) 2011-12-15
US8187585B2 (en) 2012-05-29
CA2592627A1 (en) 2006-07-27
CN101107009B (zh) 2014-08-06
WO2006078213A1 (en) 2006-07-27
PL1838341T3 (pl) 2014-04-30

Similar Documents

Publication Publication Date Title
HUS1900035I1 (hu) Kalcitonin gén-rokon peptid ellen irányuló antagonista ellenanyag
EP2093287A4 (en) PEPTIDE BINDER IGG
BRPI0907363A2 (pt) Métodos e composições relativos a peptídeos e proteínas com elementos de c-terminal
EP2118122A4 (en) NOVEL ANTIMICROBIAL PEPTIDES
DE602005015131D1 (de) Interleukin-15-antagonistisches peptid
EP1961761A4 (en) Novel peptide compound
PL1888031T3 (pl) Preparaty analogu glp-1
IL241890A0 (en) Compositions comprising a viral vector containing a recombinant neurotrophic protein
ATE451392T1 (de) Gegen amyloid-beta peptid gerichtete antikörper
BRPI0818288A2 (pt) Proteínas conjugadas e peptídeos.
ATE482281T1 (de) Plastiden transit peptide
PT2339014E (pt) Métodos e composições compreendendo aminoácidos não-naturais
BRPI0814060A2 (pt) Peptídeos ligantes tendo um domínio de ligação específico disposto em c-terminal
EG26619A (en) PEG-quadrangle arbor polymer for binding to proteins and peptides
ZA200705943B (en) Survivin peptide vaccine
DE602007011923D1 (de) Hepatocytenwachstumsfaktor-(hgf-)bindungsproteine
BRPI0819092A2 (pt) Evolução direcionada usando proteínas que compreendem aminoácidos não naturais.
PL1838341T3 (pl) Kompozycja szczepionki obejmująca białko wiążące fibronektynę lub peptyd wiążący fibronektynę
DK2001518T3 (da) Cykliske natriuretiske peptidfremstillinger
EP2078082A4 (en) RECOMBINANT HUMAN INTERFERONIAL PROTEINS
EP1735335A4 (en) Cell-killing peptide
ATE547425T1 (de) Optimiertes dengue-virus-eintrittshemmendes peptid (dn81)
DE602005012757D1 (de) Antibakterielles Peptid
EP1968623A4 (en) Bacteriocin BROKER PEPTIDE
FI20050753L (fi) Uudet peptidit